Clinical Trial Update: Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating disitamab vedotin combined with sintilimab and S-1 for HER2-overexpressing gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• S-1 (tegafur/gimeracil/oteracil)
• Sintilimab (sintilimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN